76 results about "Malignant cells" patented technology

The invention discloses a multi-omics pathological analysis system and method for colorectal cancer liver metastasis risk prediction, and relates to the technical field of biomedicine and cancer diagnosis, the system comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; according to the method, multiple omics data including the single cell data set, the space transcriptome data, the batch RNA-seq data, the clinical data and the full slice image WSIs are integrated, comprehensive and accurate prediction of the colorectal cancer liver metastasis risk is achieved, cross-dimensional data fusion and analysis improve the prediction accuracy and reliability, and the risk of the colorectal cancer liver metastasis is reduced. The invention also provides a powerful tool for deeply exploring the molecular mechanism of tumorigenesis, development and metastasis, and particularly in a cell analysis module, cell subtypes and molecular characteristics closely related to liver metastasis can be disclosed by identifying and analyzing malignant cell subgroups LMTMCs triggering liver metastasis, so that the liver metastasis can be discovered. And a scientific basis is provided for formulating a personalized treatment scheme.

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

A pathological diagnosis support device comprises: an acquisition unit that acquires pathological images including cells as subjects; a determination unit that determines whether malignant cells are included in the pathological images by inputting the pathological images to a machine-trained first classification model; a classification unit that classifies the pathological images by class by inputting the pathological images to a second classification model machine-trained to classify the pathological image into any of a plurality of classes including one or more features suggesting the presence of malignant cells; and an output unit that outputs a classification result and supports a user's decision making.

The application discloses a multi-omics pathological analysis system and method for predicting the risk of colorectal liver metastasis, relates to the technical field of biomedical and cancer diagnosis, and comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; the application realizes comprehensive and accurate prediction of the risk of colorectal liver metastasis by integrating multi-omics data, including single-cell data sets, spatial transcriptome data, batch RNA-seq data, clinical data and whole slide image WSIs; the cross-dimension data fusion and analysis not only improve the accuracy and reliability of prediction, but also provide a powerful tool for in-depth exploration of the molecular mechanism of tumor occurrence, development and metastasis, especially in the cell analysis module, identification and analysis of the malignant cell subpopulation LMTMCs triggering liver metastasis can reveal cell subtypes and molecular characteristics closely related to liver metastasis, thereby providing a scientific basis for formulating a personalized treatment plan.

The application belongs to the technical field of medicine, and discloses a method and system for detecting mucinous pancreatic cystic tumor, acquires a pancreatic cyst fluid sample; performs organoid culture on the pancreatic cyst fluid to obtain a mucinous pancreatic cystic tumor organoid; acquires cell morphology data of the mucinous pancreatic cystic tumor organoid; acquires H&E staining data and IHC detection data of the mucinous pancreatic cystic tumor organoid; acquires immunofluorescence detection data of the mucinous pancreatic cystic tumor organoid; performs scRNA-Seq sequencing on the mucinous pancreatic cystic tumor organoid to complete detection of the mucinous pancreatic cystic tumor; and the method can efficiently culture organoids and be used for verifying potential existence of malignant cells in function.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

The invention discloses a chimeric antigen receptor exosome targeting a CD8T cell, a CAR-T cell and a construction method and application of the chimeric antigen receptor exosome, and relates to the technical field of biomedicine, and the construction method comprises the following steps: co-transfecting three plasmids, namely BRD-PTK-CD8 < + >-Lamp2b, pcDNA3.1-CD63-L7Ae and pcDNA3.1-N6 (SP)-Nb60-T20-C / D box, into a 293F cell, incubating, and purifying to obtain the exosome capable of targeting the CD8T cell. The exosome can deliver CAR-mRNA to T cells and convert CD8 + cells into CAR-T cells, and blood of an infected person does not need to be drawn; cAR molecules aiming at in-vivo malignant cells can be prepared in vivo; chemotherapy and radiotherapy are not needed, and side effects are avoided; and universality is achieved.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The present invention relates to chimeric checkpoint receptor (CCR) fusion proteins, nucleic acid molecules encoding said fusion proteins, vectors comprising said nucleic acid molecules, host cells comprising said nucleic acid molecules and / or expressing said fusion proteins, methods of providing said host cells, pharmaceutical compositions comprising said fusion proteins, nucleic acid molecules or host cells, and said products for use as medicaments and in the treatment of B-cell lymphoma.

The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.

Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part, thereby inhibiting the metastatic and invasive growth of malignant cells in a cancer patient.

The invention belongs to the field of biological medicines, and particularly relates to application of a combination of ZNF496 protein and KDM2B protein in a medicine for treating cervical cancer. According to the invention, the interaction relationship of the ZNF496 protein and the interaction protein KDM2B thereof is proved for the first time, the inhibition effect of the combination of the ZNF496 protein and the interaction protein KDM2B thereof on an NF-kappa B pathway in cervical cancer cells is provided for the first time, and the application of the ZNF496 protein and the interaction protein KDM2B thereof in inhibiting malignant cell biological behaviors of the cervical cancer cells is provided for the first time. By means of the mechanism, a specific targeted therapy scheme can be designed, and the specific targeted therapy scheme is applied to preparation of ZNF496 and KDM2B combined overexpression preparation drugs and implementation of accurate individualized treatment on cervical cancer patients and has important application prospects in clinical treatment.

The invention relates to the field of biomedicine, and discloses a pancreatic cancer dependency gene score prognosis model construction method based on multi-algorithm optimization, which can utilize a machine learning algorithm to identify biomarkers related to pancreatic cancer prognosis and survival, construct a prognosis model and improve the prognosis accuracy. Comprising the following steps: identifying the activity of pancreatic cancer malignant cells and pancreatic cancer dependent genes; identifying a PADG subgroup by consistent clustering; constructing a prognosis model; performing prognosis gene correlation analysis; the invention relates to machine learning prognosis model immunotherapy assessment based on pancreatic cancer dependent gene scoring. The kit has the advantage that the risk and prognosis of the pancreatic cancer patient receiving immunotherapy can be accurately predicted. The treatment effect is improved, and the lifetime of a patient is prolonged. Discovery of a new treatment target is facilitated, and development of the pancreatic cancer treatment field is promoted.

The present disclosure relates to polynucleotides and methods of inhibiting the activities of development-associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primary or secondary solid tumors.

The invention provides a proliferative cell proportion evaluation method and device, electronic equipment and a storage medium. The method comprises the following steps: acquiring transcriptome data of malignant cells and acquiring immunofluorescence data; acquiring cell classification labels of the malignant cells according to the transcriptome data and the immunofluorescence data of the malignant cells; screening model feature genes according to the transcriptome data of the malignant cells and the cell classification tags of the malignant cells based on a first evaluation model; obtaining target transcriptome data of the malignant cells from the transcriptome data of the malignant cells based on the model characteristic genes; and inputting the target transcriptome data of the malignant cells and the cell classification labels of the malignant cells into a second evaluation model for model training to obtain a trained second evaluation model. Compared with the prior art, the method has the advantages that the proliferative cell proportion is evaluated through the evaluation model, the evaluation result does not need to be manually interpreted, the probability of personal errors is reduced, and the possibility that the evaluation result of the proliferative cell proportion has errors is reduced.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The disclosure relates to a method for detecting the presence of at least one datum representative of malignant cell proliferation within a histopathology image, the method being implemented within an electronic processing device. Such a method comprises: - dividing up (S01) an image representative of a tissue section, delivering a set of tiles of predetermined size, each tile having a position within the image representative of the tissue section; - determining (S02), for each tile of the set of tiles, a datum representative of a number of malignant cells and a datum representative of a total number of cells, these data being inserted into a first matrix Mp and into a second matrix Mt, respectively, each element of which is associated with one tile position within the image representative of the tissue section; - detecting (S03) the presence of malignant cell proliferation within the histopathology image, this involving computing data clusters of the first matrix Mp and of the second matrix Mt with a parallel-computing algorithm.

The invention relates to the technical field of biological medicine, in particular to a synthesis method and application of pinenyl thiazolidone derivatives, and the synthesis method comprises the step of synthesizing thiosemicarbazide A at the yield of 90% under the promotion of hydrochloric acid through condensation reaction between myrtenal and 4-methyl-3-thiosemicarbazide. Cyclizing the compound A and chloroacetic acid to obtain a key intermediate thiazolidone B; then, the intermediate reacts with substituted benzaldehyde, and the target compound C1-C13 is obtained. The adopted substrate myrtenal has a better anti-proliferation effect on malignant cells, strong water solubility is enhanced by introducing thiazolidines, and remarkably enhanced anti-cancer activity can be shown by introducing the thiazolidine derivative modified by Schiff base. The series of products are novel in structure, high in yield, simple in separation and purification operation and suitable for mass production, and part of products such as C5 have good biological activity.

Embodiments of the present application disclose a pan-cancer cell recognition model training method, device, equipment and storage medium. The method comprises selecting transcriptome test data of a plurality of preset cancer types according to a preset ratio of normal cells and malignant cells to construct an initial data set; obtaining a preset number of high variable genes in the transcriptome test data of the initial data set as training features to obtain a training set; based on a binary classification label, performing label annotation on the transcriptome test data in the training set to generate a binary classification label system test data set; taking the pre-training weight of a preset base model as an initialization parameter, mounting a binary classification head at the top layer of a transformer layer, and performing parameter fine-tuning on the preset base model based on the binary classification label system test data set to obtain a pan-cancer cell recognition model. The scheme of the embodiments of the present application can realize accurate identification of benign and malignant cells in pan-cancer single-cell transcriptome data.

The present application is related to a method for in situ detection of multiple lung cancer-related markers in live circulating malignant cells, and tumor heterogeneity, including accurately detecting at least one lung cancer-related nucleic acid marker in live lung cancer cells by using a lung cancer-targeted nanoprobe loaded with a plurality of molecular beacons to reflect levels of different markers in the lung cancer cells from a single cell level and a heterogeneous state of a tumor of a specific patient. The nanoprobe is a nanoparticle self-assembled from a high polymer material, an electropositive protein, a functional polypeptide and / or a functional aptamer, and a molecular beacon of a lung cancer-related marker. The nanoprobe can be used to target different phenotype circulating malignant cells in whole blood, detect nucleic acid markers in living cells, and reflect levels of different markers in the malignant cells from a single cell level.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The invention relates to the technical field of biology, and discloses a method for discovering a new stomach-tumor target spot and a system establishment method. By integrating single cell second-generation sequencing and third-generation full-length transcriptome technologies and adopting a CopyKat and Infercnv dual algorithm model, the technical limitations that tumor heterogeneity cannot be analyzed by traditional batch sequencing and full-length new transcripts and malignant cells are difficult to accurately identify by conventional single cell sequencing are overcome. The method can systematically and precisely complete the whole process from cell subset analysis, malignant cell identification to brand new membrane protein target discovery, and further improves the reliability and transformation application potential of the discovered target through cross-platform verification and function correlation analysis, and has a wide application prospect. And a more efficient and reliable target spot discovery scheme is provided for gastric cancer targeted therapy and prognosis judgment.

The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18.

To provide a physical therapy for malignant tumors that is gentle to a living body, inexpensive, and highly effective.SOLUTION: Malignant cells are killed by: forming micropores in the malignant cells by shock wave irradiation, focused high-intensity ultrasound irradiation, photoimmunotherapy, or simultaneous application of microbubbles and ultrasound; and diffusing hydrogen ions, which are present in a large amount in an extracellular fluid of the malignant cells, into the malignant cells by Lorentz force.SELECTED DRAWING: None